ArticleActa cirurgica brasileira2026
Evaluation of agmatine efficacy in contrast-induced nephropathy: experimental evidence in rat model.
Article in Acta cirurgica brasileira, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the biochemical and histopathological efficacy of agmatine as a protective agent in experimental rat contrast-induced nephropathy (CIN) model.
methodsTwenty-eight male Sprague Dawley rats were randomized into four groups: sham (no intervention), contrast agent (single dose 10 mL/kg iohexol iv), contrast agent + agmatine (single dose 10 mL/kg iohexol iv + 20 mg/kg po agmatine three days) and contrast agent + placebo (single dose 10 mL/kg iohexol iv + 1 mL of 0.9% saline ip). Biochemical and histopathological evaluations were accomplished on the fourth day, including measurements of cystatin-C, malondialdehyde (MDA), glutathione peroxidase (GPx), interleukin (IL)-1 β, superoxide dismutase (SOD), and tumor necrosis factor (TNF)-α.
resultsThe contrast agent group exhibited elevated cystatin-C, IL-1β, TNF-α, and MDA levels, with decreased SOD and GPx levels. The agmatine treatment group showed decrease in cystatin-C, IL-1β, TNF-α, and MDA, along with increased GPx and SOD levels. Histopathological evaluation revealed nephrotoxic effects in the contrast agent and placebo groups, whereas agmatine-treated rats displayed a significant reduction in tubular damage.
conclusionAgmatine administration along side contrast exposure demonstrated protective effects against CIN, evidenced by biochemical and histopathological improvements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.